MaxLinear price target raised to $28 from $23 at Benchmark

Benchmark raised the firm’s price target on MaxLinear to $28 from $23 and keeps a Buy rating on the shares. As inventory headwinds ease and new product ramps begin to contribute meaningfully over the next several quarters, the firm is “increasingly upbeat” on the setup into the second half, the analyst tells investors.